← Leaderboards
Edward Ayoub
University Of Rochester
$273,596
Attributed
$273,596
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $81.6K · FY2018–24$100K$75K$50K$25K$0
'18
'19
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$273,596 · 2
By mechanism
F32$226,366 · 1
F31$47,230 · 1
Top collaborators
No co-investigators on record.
Most similar at University Of Rochester
Same institution · by research overlap
- Craig A Mullen$2,209,306
- Martha Susiarjo$5,524,046
- James Palis$20,960,389
- B. Paige Lawrence$23,471,485
- Lisa Madalen Niswander$530,027
Others in their field
Other Emerging Leaders on “Lambda Spi-1”
- Erik Naylor · Hafion, Llc$310,592
- Maria Lara-Tejero · Yale University$104,688
- Beatrice Herrmann · University Of Pennsylvania$92,788
Research focus
Lambda Spi-1MyelogenousEnhancersKnock-DownLeukemiaMouse ModelCollaborationsDna BindingHematopoietic Stem CellsIn Vivo Model3q26Binding SitesMolecularBone MarrowAtac-SeqChromatinAcute Myelocytic LeukemiaChip-SeqEvi1 GeneGenesBindingInsightBinding ProteinsMyeloid Progenitor Cells
Grant awards (5)
Targeting Quiescence Pathways to Overcome Chemoresistance in EVI1-Overexpressing Leukemia$81,592
F32 · FY2024 · CA · contact PI
Targeting Quiescence Pathways to Overcome Chemoresistance in EVI1-Overexpressing Leukemia$74,492
F32 · FY2023 · CA · contact PI
Targeting Quiescence Pathways to Overcome Chemoresistance in EVI1-Overexpressing Leukemia$70,282
F32 · FY2022 · CA · contact PI
Therapeutic Strategies for Anemia in 3q26 Rearranged Leukemia$2,828
F31 · FY2019 · HL · contact PI
Therapeutic Strategies for Anemia in 3q26 Rearranged Leukemia$44,402
F31 · FY2018 · HL · contact PI